Literature DB >> 2818259

Neurocysticercosis. Short course of treatment with albendazole.

F Alarcón1, L Escalante, G Dueñas, M Montalvo, M Román.   

Abstract

Eighteen patients with nonenhancing parenchymal brain cysts were treated with albendazole; 9 patients were treated for 3 days and 9 patients for 1 month at daily doses of 15 mg/kg of body weight. Three months after starting therapy, results showed that in both groups the treatment was highly effective. Control studies carried out in the same group before the trial did not show any significant improvement. Five patients were controls and were treated only with symptomatic drugs. The total diameter of the lesions was reduced from 220.1 mm to 52.1 mm, which signifies a reduction of 76.3% in patients treated for a period of 3 days, and from 278.5 mm to 82.1 mm, which is 70.5%, in patients treated for 30 days. We conclude that albendazole administered according to the 3-day therapeutic scheme proposed above is as highly effective for the treatment of parenchymal brain cysticercosis as the 30-day scheme.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2818259     DOI: 10.1001/archneur.1989.00520470099034

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  Dexamethasone increases plasma levels of albendazole.

Authors:  H Jung; M Hurtado; M T Medina; M Sanchez; J Sotelo
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

2.  Albendazole in neurocysticercosis.

Authors:  D Kapil; P Vohra
Journal:  Indian J Pediatr       Date:  1993 Jan-Feb       Impact factor: 1.967

3.  Oral albendazole in the management of extraocular cysticercosis.

Authors:  R Sihota; S G Honavar
Journal:  Br J Ophthalmol       Date:  1994-08       Impact factor: 4.638

Review 4.  Anthelmintics for people with neurocysticercosis.

Authors:  Katharine Abba; Sridharan Ramaratnam; Lakshmi Narasimhan Ranganathan
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

5.  A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children.

Authors:  A K Dutta; M A Phadke; A C Bagade; V Joshi; A Gazder; T K Biswas; H H Gill; S C Jagota
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

Review 6.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

7.  Use of enzyme-linked immunosorbent assay and enzyme-linked immunoelectrotransfer blot for the diagnosis and monitoring of neurocysticercosis.

Authors:  C Simac; P Michel; A Andriantsimahavandy; P Esterre; A Michault
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

8.  Prevalence, Response to Cysticidal Therapy, and Risk Factors for Persistent Seizure in Indian Children with Neurocysticercosis.

Authors:  Animesh Kumar; Anirban Mandal; Sheela Sinha; Amitabh Singh; Rashmi Ranjan Das
Journal:  Int J Pediatr       Date:  2017-01-10

9.  Anthelmintics for people with neurocysticercosis.

Authors:  Edward J M Monk; Katharine Abba; Lakshmi N Ranganathan
Journal:  Cochrane Database Syst Rev       Date:  2021-06-01

10.  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.

Authors:  Jong-Yil Chai; Bong-Kwang Jung; Sung-Jong Hong
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.